Medison has contributed to a private placement in support of portfolio company Alpha Tau Medical’s $1bn reverse merger with Healthcare Capital Corp.
Alpha Tau Medical, an Israel-based cancer treatment technology developer backed by pharmaceutical services provider Medison Pharma, has agreed to a reverse merger deal with special purpose acquisition company Healthcare Capital Corp.
The combined business will be valued at approximately $1bn through the deal and will receive Healthcare Capital Corp’s listing on the Nasdaq Capital Market, which it secured in a $275m initial public offering in January this year.
The deal is supported by $92m in private investment in public equity…
